CD38是一类ADPR环化酶家族的II型或III型跨膜糖蛋白。作为一种多功能信号酶,它广泛表达于多种组织和细胞中。CD38在体内能够催化NAD^+(烟酰胺腺嘌呤二核苷酸)和HNADP^+(烟酰胺腺嘌呤二核苷酸磷酸)生成具有钙动员活性的第二信使核苷酸小分子:cADPR(环腺苷二磷酸核糖)和NAADP(烟酸腺嘌呤二核苷酸磷酸)等。通过作用于钙信号通路,这些Ca^2+信使小分子可以在生理条件下调控细胞内钙库钙离子的释放和外钙的内流,进而调节细胞的功能与生命活动。本论文中,采用基于配体和基于受体的虚拟筛选策略来比较野生型底物和己知抑制剂作为虚拟筛选第一步问询式的优劣性,并得到了结构新颖的抑制剂分子。采用了OpenEye公司的ROCS与EON组件对SPECS库的共216000个化合物以两类问询式进行相似性搜索,一类是天然底物包括NAADP及NAD^+,一类是抑制剂分子H2。相似性搜索得到化合物后,分别对每个化合物进行了结合模式分析及ADME预测等,最终购买由天然底物出发得到的17个化合物及由已有抑制剂出发得到的10个化合物进行测活。根据对筛选得到的分子的分子量比较、分子活性比较、结合模式比较,由抑制剂H2作为问询式出发更有可能得到结构新颖且活性更好的抑制剂。
As a type II or III transmembrane glycoprotein, human CD38 is ubiquitously expressed in all mammalian tissues. CD38 is a multi-functional enzyme and a member of the ADP-ribosyl cyclase family, and it catalyzes nicotinamide adenine dinucleotide (NAD^+) and nicotinamide adenine dinucleotide phosphate (NADP+) to two distinct Ca^2+ messengers as follows: cyclic ADP-ribose (cADPR) and nicotinic acid adenine dinucleotide phosphate (NAADP), respectively. Moreover, both cADPR and NAADP mediate mobilization of intracellular Ca^2+ targeting endoplasmic stores and the lysosomes, respectively. In this study, we combined ligand-based and structure-based virtual screening strategies to compare the inhibitor discovery efficacy based on natural substrates and the known inhibitors. The similarity queries towards SPECS database were carried out using ROCS and EON modules of OpenEye software. The hits were further docked to CD38 using AutoDock 4.05 program. In addition, ADME studies were also processed considering solubility in water and membrane permeability. Finally, we identified 17 compotmds-based on natural substrates and 10 compounds based on known inhibitor models. The results showed that the known inhibitor H2-based model was more efficient in virtual screening of CD38 non-covalent inhibitors.